Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.
Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.
Conclusion of the discussion and award presentation.
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Helping patients manage potential treatment-related adverse events is an essential part of the overall care plan in the treatment of non-small cell lung cancer. Experts provide strategies to address adverse events and best practices for providing the supportive care needed for patients.
Experts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Jenifer A. Vencill, PhD, LP, highlighted that sexual dysfunction can negatively impact patients' quality of life, and how she aims to bring more awareness to this issue.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Judy concludes the event and presents the awards.
Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.